Becton, Dickinson and Company $BDX Shares Acquired by TD Private Client Wealth LLC

Key Points

• TD Private Client Wealth LLC increased its holdings in Becton, Dickinson and Company by 39%, owning 7,244 shares valued at approximately $1.25 million.
• Becton, Dickinson and Company reported earnings per share (EPS) of $3.68 for the last quarter, exceeding estimates and showing a 10.4% revenue increase year-over-year.
• The company recently declared a quarterly dividend of $1.04, translating to an annual yield of 2.3%, with a payout ratio of 74.82%.

TD Private Client Wealth LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 39.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,244 shares of the medical instruments supplier's stock after purchasing an additional 2,034 shares during the quarter. TD Private Client Wealth LLC's holdings in Becton, Dickinson and Company were worth $1,248,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA grew its position in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. grew its position in Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Becton, Dickinson and Company by 1.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock valued at $707,872,000 after acquiring an additional 37,733 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Up 2.2%

Shares of BDX opened at $184.59 on Friday. The stock's 50-day moving average is $188.27 and its two-hundred day moving average is $188.97. The stock has a market cap of $52.91 billion, a PE ratio of 33.20, a P/E/G ratio of 1.46 and a beta of 0.27. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research reports. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler reissued a "neutral" rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research note on Thursday. They set a "sector perform" rating and a $211.00 price objective on the stock. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $213.09.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 in the last three months. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.